Glenmark Pharmaceuticals to raise $200 million via dollar bonds
The proceeds from the bond issuance will be used to refinance existing debt raised via dollar bonds in 201614-01-2020
14-01-2020
Glenmark Pharmaceuticals Ltd - 532296 - Re: Intimation Under The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ("SEBI LODR")
This is in furtherance to our letter dated May 29, 2019 whereby we had informed the stock exchanges that the Board of Directors of Glenmark Pharmaceuticals Limited ('Company') at its meeting held on May 29, 2019 had approved issuance of bonds, whether denominated in Indian Rupee or foreign currency, for an aggregate amount not exceeding USD 200 million in the international market as per applicable law. Further to the above, we hereby inform you that the Company is contemplating issuance of USD denominated notes for an aggregate amount not exceeding USD 200 million ('Notes') subject to market conditions, and the Company's officials will be participating in roadshow presentations from January 14, 2020 to January 19, 2020 covering Asia, Europe and Middle East.14-01-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Re: Intimation Under The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ("SEBI LODR")
This is in furtherance to our letter dated May 29, 2019 whereby we had informed the stock exchanges that the Board of Directors of Glenmark Pharmaceuticals Limited ('Company') at its meeting held on May 29, 2019 had approved issuance of bonds, whether denominated in Indian Rupee or foreign currency, for an aggregate amount not exceeding USD 200 million in the international market as per applicable law. Further to the above, we hereby inform you that the Company is contemplating issuance of USD denominated notes for an aggregate amount not exceeding USD 200 million ('Notes') subject to market conditions, and the Company's officials will be participating in roadshow presentations from January 14, 2020 to January 19, 2020 covering Asia, Europe and Middle East.14-01-2020
Glenmark Pharmaceuticals Ltd - 532296 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Harish KuberDesignation :- Company Secretary and Compliance Officer10-01-2020
Glenmark Pharmaceuticals Ltd - 532296 - Shareholding for the Period Ended December 31, 2019
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here09-01-2020
Cipla, Glenmark get NPPA nod for inhaler pricing over 'innovative' quotient
Glenmark had appealed to the pricing regulator in 2016 asking for a differential price for its Digihaler08-01-2020
Glenmark Pharmaceuticals gets USFDA approval for Deferasirox tablets
Glenmark Pharmaceuticals on Tuesday said it has received final approval from the United States Food & Drug Administration (USFDA) for Deferasirox07-01-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg07-01-2020
Mankind Pharma inks pact with Glenmark for anti-diabetes drug
Mankind Pharma did not give details on the brand under which it will launch the medicine.Under the agreement, Mankind Pharma will market Remogliflozin under its own trademark23-12-2019
Glenmark Pharmaceutical Inc recalls ranitidine tablets in US
The tablets have presence or potential presence of NDMA levels above the acceptable daily intake levels.Affected ranitidine tablets were distributed directly to wholesalers, distributors, retailers and repackagers nationwide22-12-2019